tofimilast
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2004 (NCT00219622)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2- Mol. weight
- 339.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL217899 ↗
Also known as
- 9-cyclopentyl-5,6-dihydro-7-ethyl-3-(thien-2-yl)-9h-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-a)pyridine
- cp-325366
- cp-325366
- tofimilast
- tofimilast
- tofimilast
- tofimilast
- tofimilast
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00150397 | Phase 2 | Mar 1, 2005 | Pfizer |
| NCT00219622 | Phase 2 | May 1, 2004 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2004 |
1 organizations
Page 1 / 1